EUVIMEDEUVIMED entdecken
Fallbericht

Recombinant Human Insulin-Like Growth Factor-1 Treatment of Severe Growth Failure in Three Siblings with STAT5B Deficiency

Gajanthan Muthuvel, Sareea Salem Al Remeithi, Corinne Foley, Andrew Dauber, Vivian Hwa, Philippe Backeljauw

Hormone Research in Paediatrics · 2024

DOI: 10.1159/000531491 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Hormone Research in Paediatrics, 2024. Verfasst von Gajanthan Muthuvel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cin…. Hauptthemen laut MEDLINE: Insulin-Like Peptides, Failure to Thrive, Insulin-Like Growth Factor I, Growth Disorders. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Patients with homozygous recessive mutations in STAT5B have severe progressive postnatal growth failure and insulin-like growth factor-I (IGF-I) deficiency associated with immunodeficiency and increased risk of autoimmune and pulmonary conditions. This report describes the efficacy and safety of recombinant human IGF-1 (rhIGF-1) in treating severe growth failure due to STAT5B deficiency. Case Presentation: Three siblings (P1, 4.4 year-old female; P2, 2.3 year-old male; and P3, 7 month-old female) with severe short stature (height SDS [HtSDS] −6.5, −4.9, −5.3, respectively) were referred to the Center for Growth Disorders at Cincinnati Children’s Hospital Medical Center. All three had a homozygous mutation (p.Trp631*) in STAT5B. Baseline IGF-I was 14.7, 14.1, and 10.8 ng/mL, respectively (all < −2.5 SDS for age and sex), and IGFBP-3 was 796, 603, and 475 ng/mL, respectively (all < −3 SDS for age and sex). The siblings were started on rhIGF-1 at 40 μg/kg/dose twice daily subcutaneously (SQ), gradually increased to 110–120 μg/kg/dose SQ twice daily as tolerated. HtSDS and height velocity (HV) were monitored over time.

Results

Six years of growth data was utilized to quantify growth response in the two older siblings and 5 years of data in the youngest. Pre-treatment HVs were, respectively, 3.0 (P1), 3.0 (P2), and 5.2 (P3) cm/year. With rhIGF-1 therapy, HVs increased to 5.2–6.0, 4.8–7.1, and 5.5–7.4 cm/year, respectively, in the first 3 years of treatment, before they decreased to 4.7, 3.8, and 4.3 cm/year, respectively, at a COVID-19 pandemic delayed follow-up visit and with decreased treatment adherence. ΔHtSDS for P1 and P2 was +2.21 and +0.93, respectively, over 6 years, but −0.62 for P3 after 5 years and in the setting of severe local lipohypertrophy and suboptimal weight gain. P3 also experienced hypoglycemia that limited our ability to maintain target rhIGF-1 dosing.

Conclusion

The response to rhIGF-1 therapy is less than observed with rhIGF-1 therapy for patients previously described with severe primary IGF-I deficiency, including patients with documented defects in the growth hormone receptor, but may still provide patients with STAT5B deficiency with an opportunity to prevent worsening growth failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin-Like PeptidesFailure to ThriveInsulin-Like Growth Factor IGrowth DisordersRecombinant ProteinsMaleSTAT5 Transcription FactorChild, PreschoolInsulin-Like Growth Factor Binding Protein 3SyndromeHumansHearing Loss, SensorineuralInfantChildSiblingsFemale

Stichwörter der Autor:innen

Growth failureGrowth hormone insensitivityRecombinant human IGF-1STAT5B

Substanzen

Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IInsulin-Like PeptidesRecombinant ProteinsSTAT5 Transcription FactorSTAT5B protein, human

Autor:innen und Institutionen

  • Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Division of Endocrinology, Department of Pediatrics, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
  • Medical Scientist Training Program, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.

Zitieren

APA

Muthuvel, G., Al Remeithi, S. S., Foley, C., Dauber, A., Hwa, V., & Backeljauw, P. (2024). Recombinant Human Insulin-Like Growth Factor-1 Treatment of Severe Growth Failure in Three Siblings with STAT5B Deficiency. Hormone Research in Paediatrics. https://doi.org/10.1159/000531491

Vancouver

Muthuvel G, Al Remeithi SS, Foley C, Dauber A, Hwa V, Backeljauw P. Recombinant Human Insulin-Like Growth Factor-1 Treatment of Severe Growth Failure in Three Siblings with STAT5B Deficiency. Hormone Research in Paediatrics. 2024. doi:10.1159/000531491

BibTeX
@article{Muthuvel2024,
  author = {Muthuvel, Gajanthan and Al Remeithi, Sareea Salem and Foley, Corinne and Dauber, Andrew and Hwa, Vivian and Backeljauw, Philippe},
  title = {Recombinant Human Insulin-Like Growth Factor-1 Treatment of Severe Growth Failure in Three Siblings with STAT5B Deficiency},
  journal = {Hormone Research in Paediatrics},
  year = {2024},
  doi = {10.1159/000531491}
}
Kostenlos starten →